Increased MTHFD2 expression is associated with acute myeloid leukemia, breast cancer, lung cancer, and liver cancer [14–20], and MTHFD2 is considered a novel target for anticancer therapy [21, 22]. Here, MTHFD2 is linked to liver cancer.